Skip to main content

Hallucinations

1
Pipeline Programs
1
Companies
5
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Acadia Pharmaceuticals
1 program
1
ACP-103Phase 25 trials
Active Trials
NCT00658567Completed123Est. Dec 2009
NCT00550238Completed459Est. May 2018
NCT00477672Completed298Est. Jul 2009
+2 more trials

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Acadia PharmaceuticalsACP-103
Acadia PharmaceuticalsACP-103
Acadia PharmaceuticalsACP-103
Acadia PharmaceuticalsACP-103
Acadia PharmaceuticalsACP-103

Clinical Trials (5)

Total enrollment: 979 patients across 5 trials

NCT00658567Acadia PharmaceuticalsACP-103

A Study of Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis

Start: Mar 2008Est. completion: Dec 2009123 patients
Phase 3Completed
NCT00550238Acadia PharmaceuticalsACP-103

A Study of the Safety and Tolerability of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis

Start: Jul 2007Est. completion: May 2018459 patients
Phase 3Completed
NCT00477672Acadia PharmaceuticalsACP-103

A Study of the Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis

Start: Jun 2007Est. completion: Jul 2009298 patients
Phase 3Completed
NCT01518309Acadia PharmaceuticalsACP-103

An Open-label Safety Study of Pimavanserin in Parkinson's Disease Patients

Start: Nov 2004Est. completion: May 201339 patients
Phase 2Completed
NCT00087542Acadia PharmaceuticalsACP-103

Treatment of Hallucinosis/Psychosis in Parkinson's Disease by an Investigational Drug

Start: Mar 2004Est. completion: Dec 200560 patients
Phase 2Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.